Ann: Mesoblast Update on COVID-19 ARDS Trial, page-268

I hope Back Pain is decent and helps stabilize the SP.

I actually hope Novartis or another pharma buys out MSB as it's at low prices at the moment with some great technology and IP.
Novartis are closest to the data and could see some value.

With market sentiment so low it might go for a bargain.

Investors are very wary of this stock - it had a bright future, but it's played out poorly.

That's life I suppose, we can look back and critise the trial design but utimately we brought on speculation and not confirmation.

Oh so close, well...over to you MSB and CLBP.